Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2033-05-06
Target enrollment:
Participant gender:
Summary
This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in
Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative
invasive Breast Cancer